Adipo-IR Calculation
Estimate adipose tissue insulin resistance using fasting free fatty acids and fasting insulin. This calculator converts common units, computes the Adipo-IR index, and visualizes where your value sits relative to broad interpretive bands used in research settings.
Results
Enter your fasting values and click the button to calculate your Adipo-IR score.
Expert Guide to Adipo-IR Calculation
Adipo-IR is short for adipose tissue insulin resistance index. It is a practical way to estimate how resistant fat tissue may be to the normal suppressive effect of insulin on lipolysis. In healthy physiology, insulin acts on adipose tissue and helps reduce the release of free fatty acids into circulation. When adipose tissue becomes insulin resistant, this brake on fat breakdown weakens. As a result, fasting free fatty acids can stay inappropriately elevated even in the presence of insulin. The Adipo-IR calculation captures that relationship by multiplying fasting free fatty acids by fasting insulin.
This matters because adipose tissue is not simply an energy storage site. It is metabolically active and participates in systemic insulin sensitivity, inflammation, hepatic fat delivery, and whole body fuel handling. A higher Adipo-IR may reflect impaired insulin action in fat tissue, greater flux of fatty acids to the liver and skeletal muscle, and increased metabolic stress. For clinicians, researchers, and informed patients, Adipo-IR can complement broader markers such as fasting glucose, HbA1c, HOMA-IR, triglycerides, waist circumference, and liver enzymes.
What is the formula for Adipo-IR?
The classic research formula is straightforward:
- Adipo-IR = fasting insulin in pmol/L × fasting free fatty acids in mmol/L
- If insulin is reported in μU/mL, convert it to pmol/L by multiplying by 6.945
- If free fatty acids are reported in μmol/L, convert to mmol/L by dividing by 1000
Example: if fasting insulin is 12 μU/mL and fasting free fatty acids are 0.55 mmol/L, insulin converts to 83.34 pmol/L. The Adipo-IR would then be 83.34 × 0.55 = 45.84. That number does not diagnose a specific disease on its own, but it provides a useful signal about adipose tissue insulin sensitivity.
Why Adipo-IR is clinically interesting
Traditional insulin resistance assessment often centers on liver and muscle physiology, especially through fasting insulin, fasting glucose, or clamp based methods. Adipo-IR focuses attention on fat tissue. That is important because dysfunctional adipose tissue can contribute upstream to several common metabolic problems. Elevated release of free fatty acids may promote hepatic glucose output, liver fat accumulation, higher triglycerides, and impaired insulin action elsewhere in the body. In many patients, adipose tissue dysfunction appears early, before frank hyperglycemia develops.
In obesity, metabolic syndrome, nonalcoholic fatty liver disease, and type 2 diabetes risk states, Adipo-IR may rise because the same insulin level is no longer suppressing lipolysis effectively. Researchers have also examined its associations with visceral adiposity, hepatic steatosis, and cardiometabolic risk patterns. It is especially helpful when interpreted as one part of a broader metabolic picture rather than as a stand alone number.
| Marker | Primary physiologic focus | Typical inputs | Best use case |
|---|---|---|---|
| Adipo-IR | Adipose tissue insulin resistance and fasting lipolysis suppression | Fasting insulin and fasting free fatty acids | Assess fat tissue dysfunction and metabolic spillover risk |
| HOMA-IR | Whole body and hepatic dominant fasting insulin resistance signal | Fasting glucose and fasting insulin | General insulin resistance screening |
| QUICKI | Insulin sensitivity estimate from fasting values | Fasting glucose and fasting insulin | Research comparisons and trend monitoring |
| Hyperinsulinemic euglycemic clamp | Reference standard for insulin sensitivity | Infusion protocol and serial glucose measurements | Advanced research and detailed phenotyping |
How to interpret the result
There is no single universal cut point that applies to every age group, laboratory method, body composition profile, or study population. That is one reason calculators should present Adipo-IR as an estimate and not as a diagnosis. Broadly speaking, lower values usually suggest better suppression of lipolysis by insulin, while higher values suggest worse adipose tissue insulin sensitivity. Trends over time can be informative if the same laboratory methods and fasting conditions are used.
- Low or favorable range: Often consistent with relatively preserved adipose insulin sensitivity, especially when fasting insulin is low normal and free fatty acids are not elevated.
- Intermediate range: May warrant correlation with waist circumference, triglycerides, glucose, liver function tests, and family history.
- Higher range: Suggests stronger evidence of adipose tissue insulin resistance and should be reviewed alongside the full clinical picture.
The calculator above uses broad bands for educational interpretation only. Real clinical judgment depends on the population being assessed, medication use, body composition, fasting duration, acute illness, and laboratory variation.
Reference statistics and population context
Population statistics vary significantly by cohort, ethnicity, age, obesity prevalence, and assay method. Even so, published metabolic research consistently shows that insulin resistant and obesity associated groups tend to have higher fasting insulin, altered free fatty acid suppression, and higher adipose insulin resistance indices than lean insulin sensitive control groups. The table below summarizes commonly reported directional patterns rather than fixed diagnostic thresholds.
| Population pattern | Typical fasting insulin tendency | Typical fasting FFA tendency | Expected Adipo-IR tendency |
|---|---|---|---|
| Lean and metabolically healthy adults | Often around 2 to 8 μU/mL | Often around 0.3 to 0.6 mmol/L | Usually lower relative to insulin resistant groups |
| Overweight or central adiposity pattern | Often around 8 to 15 μU/mL | Often around 0.4 to 0.7 mmol/L | Frequently intermediate to elevated |
| Metabolic syndrome or marked insulin resistance pattern | Often above 15 μU/mL | Often 0.5 mmol/L or higher, though variable | Often clearly elevated |
| Type 2 diabetes risk phenotype or fatty liver phenotype | Commonly elevated, but variable with beta cell status | Frequently impaired suppression pattern | Often elevated when adipose dysfunction is present |
For broader public health context, the Centers for Disease Control and Prevention notes that roughly 38.4 million people in the United States have diabetes, which is about 11.6 percent of the population, and about 97.6 million adults have prediabetes. These figures do not define Adipo-IR directly, but they highlight why early metabolic risk identification matters. In addition, the National Institute of Diabetes and Digestive and Kidney Diseases and major academic centers continue to emphasize the strong link between excess adiposity, insulin resistance, and cardiometabolic disease burden.
How to get the most accurate Adipo-IR calculation
- Use a true fasting sample, usually after 8 to 12 hours without calories.
- Try to use the same lab and similar testing conditions for serial tracking.
- Avoid interpreting results during acute illness, major stress, or after unusually intense exercise.
- Review medications that can affect insulin or fatty acid metabolism, such as glucocorticoids, insulin therapy, or some antidiabetic drugs.
- Interpret the result alongside waist circumference, triglycerides, HDL cholesterol, fasting glucose, HbA1c, liver enzymes, and blood pressure.
Adipo-IR versus HOMA-IR
Both indices are useful, but they answer slightly different questions. HOMA-IR is better known and easier to calculate because fasting glucose and insulin are commonly available. It is helpful for general insulin resistance screening. Adipo-IR, by contrast, is specifically designed to capture insulin resistance at the adipose tissue level by using free fatty acids instead of glucose. Someone can have a concerning Adipo-IR pattern even before fasting glucose becomes clearly abnormal. That makes the index attractive for more nuanced metabolic assessment, especially where adipose tissue dysfunction is suspected.
Limitations of Adipo-IR
Like any biomarker, Adipo-IR has limitations. First, free fatty acid assays are less commonly ordered in routine primary care than glucose and insulin, so availability can be a barrier. Second, there is no globally standardized cutoff with universal clinical adoption. Third, fasting levels represent only one snapshot and may not fully capture dynamic postprandial or clamp based physiology. Fourth, some individuals with advanced diabetes or beta cell dysfunction may have lower insulin levels despite significant metabolic disease, which can complicate simple interpretations. For these reasons, the index is best used as an adjunct marker.
Can you improve a high Adipo-IR?
In many people, yes. Strategies that improve insulin sensitivity often improve adipose tissue function as well. The strongest foundations are sustained energy balance improvement, regular physical activity, reduced visceral fat, adequate sleep, and treatment of sleep apnea when present. Diet quality matters too. Higher fiber intake, adequate protein, reduced ultra processed food intake, and attention to total caloric excess can all support better metabolic regulation. In selected patients, evidence based medical therapies may also help under clinician supervision.
Authoritative resources
For evidence based background on insulin resistance, diabetes, and obesity related metabolic risk, review these sources:
- National Institute of Diabetes and Digestive and Kidney Diseases: Prediabetes and insulin resistance
- Centers for Disease Control and Prevention: National Diabetes Statistics Report
- Harvard T.H. Chan School of Public Health: Obesity and inflammation
Bottom line
Adipo-IR is a valuable estimate of adipose tissue insulin resistance based on fasting insulin and free fatty acids. It can offer insight that standard glucose based markers may miss early in the metabolic disease process. Still, it is not a diagnosis by itself. Use it as part of a larger metabolic assessment, track it under consistent conditions, and discuss concerning results with a qualified healthcare professional. When combined with clinical history and other laboratory markers, Adipo-IR can be a powerful tool for understanding how fat tissue contributes to overall metabolic health.